ABBV AbbVie Inc.
Company Analysis
Latest News
AbbVie secures EU approval for Rinvoq, first systemic treatment for vitiligo
The European Commission approved AbbVie’s Rinvoq (upadacitinib) to treat non-segmental vitiligo in adults and adolescents aged 12 and older. This decision...
AbbVie’s RINVOQ Wins EU Approval, First JAK Inhibitor for Hair Loss
The European Commission approved AbbVie’s RINVOQ (upadacitinib) to treat severe alopecia areata in adults and adolescents aged 12 and older. This decision...
🟢 AbbVie is trading 3.1% up today on pre-earnings positioning and immunology pipeline optimism
AbbVie is trading 3.1% up at $264.85 as investors position ahead of its July 31, 2026, Q2 earnings release. • Recent analyst price-target increases and...
AbbVie and Genmab Miss Survival Goal in Phase 3 Lymphoma Trial
AbbVie and development partner Genmab announced that epcoritamab failed its primary goal in the Phase 3 EPCORE DLBCL-1 trial. The study evaluated the drug in...
AbbVie wins EU approval for Boey, a rapid-onset frown line treatment
AbbVie’s Allergan Aesthetics received European Commission approval for Boey (trenibotulinumtoxinE). The authorization covers all 30 European Economic Area...
🟢 AbbVie is trading 3.15% up today on broad healthcare sector strength
AbbVie is trading at $251.79 (+3.15%) in mid-morning trading, driven by broad strength across the healthcare sector. • The Health Care Select Sector SPDR Fund...
AbbVie lowers second quarter and full-year 2026 EPS guidance by $0.17 due to a $291 million R&D expense.
AbbVie updated its financial guidance for the second quarter and full-year 2026, lowering its adjusted EPS forecast to incorporate a significant research and...
AbbVie Faces US National Security Probe Over China Clinical Trials
A bipartisan U.S. House committee has launched a national security investigation into AbbVie's clinical drug trials in China. The probe, led by the House...
AbbVie stock jumps 4.2% on positive EU regulatory opinions for RINVOQ
AbbVie received two positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for RINVOQ (upadacitinib). The...
AbbVie Hits Phase 3 Goal, Cutting Lymphoma Progression Risk by 60%
AbbVie announced positive topline results from its Phase 3 EPCORE DLBCL-4 trial for epcoritamab on June 29, 2026. The study evaluated epcoritamab in...
AbbVie shares jump 17%, driven by pediatric approvals and Apogee deal
AbbVie reported a 17% increase in its stock price during June 2026. The company secured expanded European Union approval for MAVIRET to treat acute and...
🟢 ABBV is trading 3.4% up today on $10.9 billion all-cash Apogee acquisition
ABBV is trading 3.4% higher at $251.38 following the announcement of a $10.9 billion all-cash acquisition of Apogee Therapeutics to expand its immunology...
🟢 ABBV is trading 3.1% up today following $10.9 billion acquisition of Apogee Therapeutics
• AbbVie announced the acquisition of Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction. • The deal is expected to expand AbbVie's...
🟢 ABBV surges 6.1% in pre-market on continued momentum from $10.9 billion Apogee Therapeutics acquisition
ABBV is trading at $229.70, up 6.1% in pre-market, extending gains following its strategic acquisition of Apogee Therapeutics. • The pharmaceutical giant...
🟢 AbbVie Inc. extends move to 5.4% up
ABBV is trading at $228.10, up 5.4% versus the comparison close of $216.49 during regular trading. This is a price-movement alert; no separate company-specific...
AbbVie to acquire Apogee Therapeutics for $10.9B to expand immunology pipeline
AbbVie has entered into a definitive agreement to acquire Apogee Therapeutics, a clinical-stage biotechnology company, in an all-cash transaction valued at...
AbbVie Nears $10.9 Billion Apogee Deal, Strengthening Immunology Pipeline
AbbVie is nearing a $10.9 billion cash agreement to acquire Apogee Therapeutics. The proposed deal values the clinical-stage biotech at a 60% premium over its...
AbbVie Unveils Venclexta and Epcoritamab Data, Bolstering Oncology Market Position
AbbVie is presenting new blood cancer portfolio data at the European Hematology Association (EHA) 2026 Congress. Presentations include updates on approved and...
🟢 AbbVie Inc. shares rise 3.6% after its cancer drug Elahere wins NHS approval in England
AbbVie Inc. is trading at $225.00 (+3.6%) in pre-market after its ovarian cancer drug, Elahere, was approved for use by the NHS in England. • The approval...
🟢 AbbVie Inc. is trading 3% up today as shares extend a multi-day rebound amid a rotation into defensive healthcare
AbbVie Inc. is trading 3% up at $223.65, extending its recent multi-day rebound from last week’s pullback despite a lack of fresh company-specific...